Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
“This acquisition has the potential to accelerate the availability of important rare disease medicines to more patients worldwide. The FTC’s complaint impacts patients and is rooted in a theory about potential future “bundled” contracts with payors and not competitive overlap concerns. Horizon does not and has no plans to bundle any of its rare disease medicines. It is imperative that we continue to advocate for access to innovative treatments for patients who may benefit, particularly in diseases with significant unmet needs, and the proposed transaction with Amgen is part of that mission. We firmly believe in the benefits of this acquisition and intend to work with the court on a schedule that would allow the transaction to close by mid-December.”
About Horizon
Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
Forward-Looking Statements
This announcement contains forward-looking statements, including statements regarding Horizon’s future prospects, developments and business strategies, the potential outcome of litigation with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005835/en/
Investors:
Senior Vice President, Chief Investor Relations Officer
Investor-relations@horizontherapeutics.com
Executive Vice President, Corporate Affairs and Chief Communications Officer
media@horizontherapeutics.com
Ireland Media:
Associate Director, Corporate Communications
media@horizontherapeutics.com
Source: